SV | Jotup

Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis

Retrieved on:

Thursday, May 9, 2024

Cancer, OGM, Chord diagram (information visualization), Doctor of Philosophy, Aneuploidy, VIA, Classification, Genomics, SVS, SAN, Medical imaging

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis.

Key Points:

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis.
These advancements to the company’s VIA™ software solution enhance the detection and interpretation of aneusomies, and improve the analysis, visualization, interpretation, and reporting of data types including optical genome mapping (OGM), next generation sequencing, and microarray, for comprehensive assessment of hematological diseases.
These advancements to our VIA software and Bionano Solve pipeline offer researchers working with OGM data more precise and sensitive detection methods for genomic research.
We believe the upgrades announced today will improve researchers’ ability to visualize, interpret and report results in a streamlined process that offers greater utility for the identification of critical cancer signatures from a genome-wide perspective,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.

Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress

Retrieved on:

Wednesday, May 8, 2024

Reiterated full year 2024 revenue guidance of $37.0 to $41.0 million; revenue for the second quarter of 2024 is expected to be $7.8 to $8.2 million.

Key Points:

Reiterated full year 2024 revenue guidance of $37.0 to $41.0 million; revenue for the second quarter of 2024 is expected to be $7.8 to $8.2 million.
GAAP gross margin for the first quarter of 2024 was 32%, compared to 28% from the first quarter of 2023.
First quarter 2024 non-GAAP gross margin was 34%, compared to 30% from the first quarter of 2023.
Gülsen Kama, chief financial officer at Bionano added, “Q1 2024 was an important quarter for the Company.

CesiumAstro Selected by Rocket Lab to Provide Multi-Beam Ka-Band Communications Payloads for its Space Development Agency Tranche 2 Transport Layer Constellation

Retrieved on:

Tuesday, May 7, 2024

CesiumAstro, an industry leader in active phased array communications technology for space and airborne systems, announced today that the company was selected by Rocket Lab (Nasdaq: RKLB) to provide its Vireo active electronically scanned array (AESA) radio frequency (RF) communications payload for integration on 18 space vehicles (SVs) supporting the Space Development Agency’s (SDA’s) Tranche 2 Transport Layer (T2TL).

Key Points:

CesiumAstro, an industry leader in active phased array communications technology for space and airborne systems, announced today that the company was selected by Rocket Lab (Nasdaq: RKLB) to provide its Vireo active electronically scanned array (AESA) radio frequency (RF) communications payload for integration on 18 space vehicles (SVs) supporting the Space Development Agency’s (SDA’s) Tranche 2 Transport Layer (T2TL).
Image courtesy: CesiumAstro
CesiumAstro’s Vireo payload is the culmination of more than seven years of the company’s AESA research, development, testing, and manufacturing.
When fully operational, the Transport Layer constellation will include hundreds of SVs operating in low-Earth orbit, including 90 total Beta Program configurations.
“We’re pleased to be flying the CesiumAstro Vireo communications payload,” said Rocket Lab’s Vice President of Space Systems, Brad Clevenger.

Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing

Retrieved on:

Thursday, April 11, 2024

B-ALL, OGM, RNA, WGS, Genetic variation, Doctor of Philosophy, Research, Leukemia, Bone marrow, Biomarker, Genomics, Whole genome sequencing, Cancer, SVS, SAN, Vaccine

The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.

Key Points:

The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.
The study concluded that OGM together with WGS can potentially identify new therapeutic targets and improve personalized medicine in pediatric leukemia and other cancers by providing a more complete view of genome variation, including structural variation.
The study findings showed that, of the 3,075 total SVs detected in the B-ALL samples, 1,255 were uniquely detected by OGM.
The study also found that WGS detected 66 gene fusions, and that OGM was able to detect an additional 56 fusions that were missed by WGS.

Navigate Your Path: Exploring the 2024 Nissan Pathfinder Trim Levels at Palm Springs Nissan

Retrieved on:

Wednesday, April 17, 2024

SUV, Pathfinder, Nissan Frontier, Research, Platinum, Online shopping

CATHEDRAL CITY, Calif., April 17, 2024 /PRNewswire-PRWeb/ -- Palm Springs Nissan, a leading Nissan dealership in California, is proud to announce the launch of its informative research page dedicated to the versatile 2024 Nissan Pathfinder. Palm Springs drivers seeking an SUV that adapts to their needs can now explore the various trim levels to find their perfect fit.

Key Points:

Palm Springs Nissan now offers detailed research on the exciting 2024 Nissan Pathfinder, a midsize pickup that is powerful, versatile, and affordable.
CATHEDRAL CITY, Calif., April 17, 2024 /PRNewswire-PRWeb/ -- Palm Springs Nissan, a leading Nissan dealership in California, is proud to announce the launch of its informative research page dedicated to the versatile 2024 Nissan Pathfinder.
Palm Springs drivers seeking an SUV that adapts to their needs can now explore the various trim levels to find their perfect fit.
Having virtually explored the 2024 Nissan Pathfinder, Palm Springs Nissan invites Coachella Valley residents to visit their showroom and experience the SUV firsthand.

Press release - Parliament approves first ever EU rules on combating violence against women

Retrieved on:

Thursday, April 25, 2024

Marriage, EPP, Domestic violence, Religion, Health care, Female, S&D, Crime, Fear, Disclosure, Parliament, Commission, Woman, Outline, Rape, Safety, Offense, European, Legislation, Violence

Parliament approves first ever EU rules on combating violence against women

Key Points:

Parliament approves first ever EU rules on combating violence against women
- Actions to prevent rape and increase understanding of consent
- Forced marriage and female genital mutilation considered crimes
- Disclosing private information online without consent is prohibited, as is “cyber-flashing”
- Specialised assistance for victims
The new rules aim to prevent gender-based violence and protect its victims, especially women and victims of domestic violence.
Parliament adopted on Wednesday, with 522 in favour, 27 against, and 72 abstentions, the first ever EU rules on combating violence against women and domestic violence.
The directive calls for stronger laws against cyberviolence, better assistance for victims, and steps to prevent rape.
The new rules prohibit female genital mutilation and forced marriage and outline particular guidelines for offenses committed online, such as the disclosure of private information and cyberflashing.

EQS-News: JDC Group AG confirms preliminary figures for 2023

Retrieved on:

Wednesday, April 10, 2024

EUR, Growth, CFO, Share repurchase, Sale, JDC, Insurance, VKB, Eye, Annual report, DMS, Security (finance)

JDC thus received around 13 million Euro in liquid funds.

Key Points:

JDC thus received around 13 million Euro in liquid funds.
Hidden reserves of around 7 million Euro were raised, increasing the equity of the JDC Group.
Pool GmbH, achieved a very pleasing placement result of 20 million Euro for its new 2023/2028 bond (ISIN DE000A3514Q0).
The full 2023 Annual Report can be found at www.jdcgroup.de in the Investor Relations section.

Bionano Announces 9 Poster Presentations and Introduces New High Throughput Stratys™ System at the American Association for Cancer Research Annual Meeting

Retrieved on:

Tuesday, April 2, 2024

SAN, NGS, Research, Classification, Cancer, Software, AACR, Genomics, VAF, Bone marrow, OGM, VIA, Medicine, Medical imaging

AACR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine.

Key Points:

AACR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine.
The AACR conference will be held April 5-10, 2024, in San Diego, California.
Bionano will introduce its new Stratys™ system, which offers higher throughput and improved sample flexibility, to the cancer research community at the conference.
Nine scientific poster presentations will illustrate OGM’s utility for cancer research in areas including solid tumors, hematological malignancies, as well as applications in cell and gene therapy and cell manufacturing and bioprocessing quality control.

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Retrieved on:

Tuesday, March 19, 2024

Ovarian cancer, DNA repair, Breast, SAN, Neoplasm, DNA, HBOC, Doctor of Philosophy, Medicine, Genomics, Chromothripsis, SVS, Breast cancer, HRD, BRCA2, OGM, BRCA1, Drug resistance, Medical imaging

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.

Key Points:

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
“We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.

BioSkryb Genomics to Present Novel Research on Tumor Heterogeneity at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on:

Thursday, March 28, 2024

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.

Key Points:

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.
“Tumor heterogeneity is a key challenge for researchers in the cancer research field.
As tumors evolve, subclones emerge with mutations that convey adaptive phenotypes, including resistance to therapies,” said Suresh Pisharody, CEO of BioSkryb.
“Our next generation single-cell technology gives scientists the tools to better understand the way tumors evolve with a comprehensive, scalable, and streamlined workflow.